Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Complement C5a and related anaphylatoxins (C3a, C4a) are potent bioactive protein fragments generated during the activation of the complement cascade (StatPearls: NBK534869). C5a is the most biologically active member, functioning as a powerful chemoattractant that recruits and activates neutrophils, monocytes, and macrophages to sites of inflammation. It exerts its effects primarily through the high-affinity G protein-coupled receptor C5aR1 (CD88) and the non-canonical receptor C5aR2 (UniProt: P21730). Dysregulation of the C5a-C5aR1 axis is a key driver in the pathogenesis of various inflammatory and autoimmune conditions, including ANCA-associated vasculitis, hidradenitis suppurativa, and severe COVID-19. Therapeutic strategies targeting this pathway include monoclonal antibodies that bind and neutralize C5a directly, as well as small molecule antagonists that block the C5aR1 receptor (FDA: 214472). These interventions aim to mitigate tissue damage caused by excessive leukocyte infiltration while preserving the terminal complement pathway's ability to form the membrane attack complex.
Inhibition of the anaphylatoxin signaling pathway through direct neutralization of the C5a ligand or competitive antagonism of the C5a receptor 1 (C5aR1), thereby preventing neutrophil activation and chemotaxis.
8 more in the full profile.
Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Complement C5a anaphylatoxin (C5a).